Hohmann to lead Partners IRB Program- BWH Bulletin - For and about the People of Brigham and Women's Hospital
Hohmann to lead Partners IRB Program- BWH Bulletin - For and about the People of Brigham and Women's Hospital
Skip to contents
September 18, 2000
Browse the archive
Current issue
In This Issue:
A Fitting Tribute
Survey Teams Take Action
Referral Program Extended through Dec. 31
New Appointments at BWH
I Scream, You Scream. . .
A “Taste” of Diversity at BWH
National Hispanic Heritage Month at SJPHC
Hohmann to lead Partners IRB Program
New MRI Gives More to MS Patients
Nominate a Leader
Partners in Excellence
AIDS Ride Traffic Notice
Calendar
Pike Notes
Elizabeth Hohmann, MD, an MGH infectious disease specialist, has been named chair and director of the Institutional Review Board (IRB) for Partners HealthCare System. She will direct the IRBs at BWH, MGH and affiliated sites, supervising the physician and administrative staffs, operations and policies of the Partners IRBs. IRBs are responsible for reviewing all proposed research studies involving human subjects to assure that they comply with ethical requirements and have a solid scientific basis. In recent years, the Partnerswide IRB process has been integrated in order to establish standard procedures and improve turnaround time. Currently there are two IRBs based at the BWH and two based at MGH, each of which may review studies based at either hospital. A separate IRB reviews cancer research studies conducted through Dana-Farber Partners Cancer Care. Hohmann has previously chaired IRB panels at both BWH and MGH. Eugene Braunwald, MD – who as Harvard Medical School (HMS) faculty dean for Academic Programs at Partners has academic oversight of the Partners research program – says, “I am delighted that Dr. Hohmann is willing to step up to the plate in managing this very difficult issue.” Hohmann is a graduate of HMS, trained in internal medicine at Beth Israel Hospital and in infectious disease at the MGH. In addition to her clinical infectious disease practice, she conducts research into the development of live attenuated bacterial vaccines and vaccine vectors. Hohmann is a member of a NIH study section and has served as a consultant on vaccine development for many organizations. She has been involved in clinical research in the MGH General Clinical Research Center and was among the first recipients of the Claflin Distinguished Scholar Awards for women in academic medicine.